en Computational and Systems Oncology Editorial <p style="text-align: justify;">Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte&ndash;associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These inhibitors rely on preventing immunosuppression and enhancing anti-tumor responses. Under healthy conditions, over-activation of T cell immunity is controlled by immune checkpoints, which are molecules that suppress T cell function and thereby prevent uncontrolled T cell activation and autoimmunity.<br> ....</p> Dendritic Cells, Immunotherapy, Neoplasms. 1 2 http://mcijournal.com/browse.php?a_code=A-10-101-1&slc_lang=en&sid=1 Teunis B H Geijtenbeek t.b.geijtenbeek@amc.uva.nl 10031947532846001196 10031947532846001196 Yes Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands